Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.53 |
| ▸ | MELK | Q14680 | 1/20 | 0.50 |
| ▸ | NQO1 | P15559 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 3/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.42 |
| ▸ | MAPT | P10636 | 4/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.42 |
| ▸ | HBB | P68871 | 1/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9809277 | 0.89 | APLNR (0.47) | KDM4EMELKCYP3A4ALDH1A1MAPT | |
| SCHEMBL701717 | 0.89 | APLNR (0.47) | KDM4EMELKNQO1TSHRTDP1 | |
| Hydrochloric Acid SCHEMBL2944977 | 0.87 | MELK (0.46) | KDM4EMELKNQO1TSHRTDP1 | |
| SCHEMBL5252024 | 0.84 | NQO1 (0.52) | KDM4ENQO1TSHRTDP1MEN1 | |
| SCHEMBL13990807 | 0.84 | KDM4E (0.56) | KDM4ENQO1TSHRTDP1MEN1 | |
| SCHEMBL16770699 | 0.81 | KDM4E (0.49) | KDM4ENQO1TSHRTDP1MEN1 | |
| SCHEMBL6784748 | 0.81 | KDM4E (0.53) | KDM4ENQO1TSHRTDP1MEN1 | |
| SCHEMBL7674855 | 0.81 | KDM4E (0.53) | KDM4ENQO1TSHRTDP1MEN1 | |
| SCHEMBL22273415 | 0.79 | KLKB1 (0.49) | NQO1TSHRTDP1MEN1KMT2A | |
| SCHEMBL3110685 | 0.79 | NQO1 (0.46) | NQO1TSHRTDP1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1940832-B1 | NOVEL 1-AZA BICYCLOALKYL DERIVATIVES FOR THE TREATMENT OF PSYCHOTIC AND NEURODEGENERATIVE DISORDERS | NOVARTIS AG (CH) | 2011-12-07 | — | — | EP | disclosed |
| US-20080255135-A1 | 1-Aza-bicyclo[2.2.2]octane and 1-aza-bicyclo[2.2.1]heptane derivatives; psychotic, psychological, nervous system and neurodegenerative disorders; nicotinic receptor mediated diseases | NOVARTIS AG (CH) | 2008-10-16 | — | — | US | disclosed |
| EP-1940832-A1 | NOVEL 1-AZA BICYCLOALKYL DERIVATIVES FOR THE TREATMENT OF PSYCHOTIC AND NEURODEGENERATIVE DISORDERS | Novartis AG (CH) | 2008-07-09 | — | — | EP | disclosed |
| WO-2007045478-A1 | NOVEL 1-AZA BICYCLOALKYL DERIVATIVES FOR THE TREATMENT OF PSYCHOTIC AND NEURODEGENERATIVE DISORDERS | NOVARTIS AG (CH) | 2007-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255135-A1 | 1-Aza-bicyclo[2.2.2]octane and 1-aza-bicyclo[2.2.1]heptane derivatives; psychotic, psychological, nervous system and neurodegenerative disorders; nicotinic receptor mediated diseases | CHRNA2, CHRNA10, CHRNA1 | KDM4E 2771/4885MELK 2979/4885NQO1 2188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.